Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers

被引：20
|
作者：
Özdemir, V [1 ]
Tyndale, RF
Reed, K
Herrmann, N
Sellers, EM
Kalow, W
Naranjo, CA
机构：
[1] Univ Toronto, Dept Pharmacol, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Psychopharmacol Res Program, Toronto, ON M4N 3M5, Canada
[3] Univ Toronto, Womens Coll Hosp, Psychopharmacol & Dependence Res Unit, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M4N 3M5, Canada
[5] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M4N 3M5, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON M4N 3M5, Canada
[7] Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 19卷 / 05期
关键词：
D O I：
10.1097/00004714-199910000-00014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：472 / 475
页数：4
相关论文
共 50 条
  • [21] Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
    Rasmus Steen Pedersen
    Per Damkier
    Kim Brøsen
    European Journal of Clinical Pharmacology, 2006, 62 : 513 - 521
  • [22] Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
    Suzuki, A
    Otani, K
    Mihara, K
    Yasui, N
    Kaneko, S
    Inoue, Y
    Hayashi, K
    PHARMACOGENETICS, 1997, 7 (05): : 415 - 418
  • [23] Primary bioavailability parameters of loratadine in CYP2D6 extensive metabolizers
    Kunicki, PK
    Gutkowski, P
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 525 - 525
  • [24] Pharmacokinetics of atomoxetine after administration of paroxetine in relation to CYP2D6 genotype status
    Kim, Dong-Hyun
    Lim, Hye-Jin
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E316 - E317
  • [25] Effects of dosage and CYP2D6 mutated allele on plasma concentration of paroxetine
    Sugai, T
    Sawamura, K
    Suzuki, Y
    Someya, T
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A10 - A10
  • [26] Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers
    Steimer, W
    Zöpf, K
    von Amelunxen, S
    Pfeiffer, H
    Bachofer, J
    Popp, J
    Messner, B
    Kissling, W
    Leucht, S
    CLINICAL CHEMISTRY, 2004, 50 (09) : 1623 - 1633
  • [27] Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism
    Linnet, K
    Wiborg, O
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) : 41 - 47
  • [28] Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder
    Zastrozhin, Mikhail
    Skryabin, Valentin
    Petukhov, Aleksey
    Pankratenko, Elena
    Pozdniakov, Sergei
    Ivanchenko, Valentina
    Horyaev, Denis
    Vlasovskih, Roman
    Bryun, Evgeny
    Sychev, Dmitry
    JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (10) : 1146 - 1150
  • [29] Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers.
    Shaw, AA
    Ziemniak, J
    Liu, S
    Chervenick, SW
    Rackley, RJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P77 - P77
  • [30] The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Watanabe, T
    Akiyama, K
    Shimoda, K
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (03): : 486 - 491
12345